Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s shares decreased 7.81% to $19.84. The company on Mar. 3 reported business and financial highlights for the fourth quarter and year ended December 31, 2013 and outlined the Company’s major clinical development goals for 2014. Total revenue was $0.6 million in the fourth quarter of 2013 and $4.1 million for the twelve months ended December 31, 2013, compared to $3.6 million and $11.2 million for the comparable periods in 2012. Net loss was $22.1 million, or ($0.27) per share, for the fourth quarter of 2013 and $81.6 million, or ($1.02) per share, for the twelve months ended December 31, 2013, compared to net loss of $16.8 million, or ($0.27) per share, and $59.1 million, or ($1.02) per share, for the comparable periods in 2012. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares after opening at $18.62 moved to $18.97 on last trade day and at the end of the day closed at $16.95. Company price to sales ratio in past twelve months was calculated as 193.41 and price to cash ratio as 10.05. Celldex Therapeutics, Inc. (NASDAQ:CLDX) showed a negative weekly performance of -21.24%.
Unilife Corp (NASDAQ:UNIS) settled -1.30% lower at $4.56 on above-normal volume of 1.34M shares during the last trading day. The stock has its 12-month high at $5.30 and 52-week low price was $1.80. It traded in a range of $4.40 to $4.70 during the last trading day. Unilife Corp (NASDAQ:UNIS) shares fell -8.08% in last trading session and ended the day on $3.98. UNIF return on equity ratio is recorded as -179.90% % and its return on assets is -89.50%. Unilife Corp (NASDAQ:UNIS) yearly performance is 82.57%.
TherapeuticsMD (NASDAQ:TXMD) CEO Robert G. Finizio unloaded 982,053 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $6.70, for a total transaction of$6,579,755.10. Therapeutics MD Inc (NYSEMKT:TXMD) shares moved down -0.83 % in last trading session and was closed at $6.00, while trading in range of $5.21 – 6.12 . Therapeutics MD Inc (NYSEMKT:TXMD) year to date (YTD) performance is 15.16%.
Investment analysts at Mizuho lifted their target price on shares of EXACT Sciences (NASDAQ:EXAS) from $18.00 to $22.00 in a note issued to investors on Friday, AnalystRatingsNetwork.com reports. Mizuho’s price target suggests a potential upside of 60.00% from the company’s current price. EXACT Sciences Corporation (NASDAQ:EXAS) weekly performance is -11.19%. On last trading day company shares ended up $12.86. EXACT Sciences Corporation (NASDAQ:EXAS) distance from 50-day simple moving average (SMA50) is -5.10%. Analysts mean target price for the company is $17.33.